The real-world evidence supports UZEDY's clinical and economic value but is unlikely to drive near-term revenue acceleration without a formal label expansion or updated guidance. Monitor upcoming quarterly filings for any impact on UZEDY sales trends.
Price Chart
Executive Summary
Teva presented new real-world data at Psych Congress showing that UZEDY (risperidone) extended-release injectable suspension improves treatment continuity, reduces emergency room visits and hospitalizations, and delivers over $1,000 per patient per month in direct cost savings compared to other long-acting injectables and oral antipsychotics in schizophrenia and bipolar I disorder. The data strengthens UZEDY's competitive positioning but does not change Teva's near-term financial outlook or address the recent debt refinancing.
Key Facts
- UZEDY patients had a 40% lower all-cause ED visit rate vs. paliperidone palmitate once-monthly (PP1m) in a matched cohort of 1,166 patients.
- Estimated mean monthly direct healthcare costs were $4,688.10 for UZEDY vs. $5,724.80 for PP1m, delivering adjusted mean monthly savings of $1,036.70 per patient.
- UZEDY patients achieved 3.6x higher odds of adherence vs. risperidone microspheres (OR: 3.6) and an 80% lower likelihood of discontinuation (OR: 0.2).
- In BD-I, patients switching to UZEDY experienced significantly less treatment failure (47% vs. 63%) compared to those switched to another oral antipsychotic.
- Data presented at Psych Congress, September 15–19, 2026, in New Orleans.
Financial Impact
Real-world data shows UZEDY delivers ~$1,037 per patient per month in direct cost savings vs. PP1m; no revenue or guidance impact stated.
Risk Factors
- Real-world data is observational and may not replicate in controlled settings; competitive dynamics with other long-acting injectables remain.
- No financial guidance or revenue impact was provided in the press release; the data does not change Teva's near-term earnings trajectory.
- The recent $4.5B debt refinancing (424B5 filed 2026-09-08) is a separate credit event that overshadows this product-level news for equity holders.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364952 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Press Release | $39.22 | awaiting T+60 | — | $40.39 (+2.98%) |
Oct 15, 2026 12d ago | Institutional Cluster | $41.11 | awaiting T+60 | — | $40.39 (+1.75%) |
Oct 8, 2026 19d ago | 3 | $41.10 | awaiting T+60 | — | $40.39 (−1.73%) |
Oct 2, 2026 25d ago | Press Release | $39.53 | awaiting T+60 | — | $40.39 (+2.18%) |
Oct 2, 2026 25d ago | Press Release | $39.53 | awaiting T+60 | — | $40.39 (+2.18%) |
Sep 30, 2026 27d ago | Press Release | $39.31 | awaiting T+60 | — | $40.39 (+2.75%) |
Sep 28, 2026 29d ago | Press Release | $39.81 | awaiting T+60 | — | $40.39 (+1.46%) |
Sep 23, 2026 4w ago | Press Release | $40.22 | awaiting T+60 | — | $40.39 (+0.42%) |
Sep 23, 2026 4w ago | Press Release | $40.22 | awaiting T+60 | — | $40.39 (+0.42%) |
Sep 22, 2026 5w ago | Insider Cluster | $39.01 | awaiting T+60 | — | $40.39 (−3.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers